Recursion Pharmaceuticals, Inc.
RXRXNASDAQHealthcare● Active
$3.30
$-0.02(-0.60%)
Market Cap$1.5B
P/E Ratio—
52W High$7.18
52W Low$2.77
Recursion Pharmaceuticals, Inc. (RXRX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RXRX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
-$0.22
Est. -$0.30 · +26.7%
Revenue
$0.01B
Est. $0.02B · -60.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 3-Quarter EPS Beat Streak
RXRX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.19
Rev. $0.35B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.19
Rev. Est.$0.35B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | -$0.25 | — | — | — | $0.01B | — |
| ▲ Q2 FY2026 | May 6, 2026 | -$0.30 | -$0.22 | +26.7% | $0.01B | $0.02B | -60.1% |
| ▲ Q1 FY2026 | Feb 25, 2026 | -$0.28 | -$0.21 | +25.0% | $0.04B | $0.02B | +44.0% |
| ▲ Q4 FY2025 | Nov 5, 2025 | -$0.38 | -$0.36 | +5.3% | $0.01B | $0.02B | -78.9% |
| ▼ Q3 FY2025 | Aug 5, 2025 | -$0.35 | -$0.41 | -17.1% | $0.02B | $0.02B | -4.1% |
| ▼ Q2 FY2025 | May 5, 2025 | -$0.44 | -$0.50 | -13.6% | $0.01B | $0.01B | +5.6% |
| ▼ Q1 FY2025 | Feb 28, 2025 | -$0.44 | -$0.53 | -20.4% | $0.00B | $0.02B | -76.3% |
| ▼ Q4 FY2024 | Nov 6, 2024 | -$0.33 | -$0.34 | -3.0% | $0.03B | $0.02B | +43.5% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
-$0.25
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026Beat
EPS Actual
-$0.22
EPS Est.
-$0.30
EPS Surpr.
+26.7%
Revenue
$0.01B
Q1 FY2026
Feb 25, 2026Beat
EPS Actual
-$0.21
EPS Est.
-$0.28
EPS Surpr.
+25.0%
Revenue
$0.04B
Q4 FY2025
Nov 5, 2025Beat
EPS Actual
-$0.36
EPS Est.
-$0.38
EPS Surpr.
+5.3%
Revenue
$0.01B
Q3 FY2025
Aug 5, 2025Miss
EPS Actual
-$0.41
EPS Est.
-$0.35
EPS Surpr.
-17.1%
Revenue
$0.02B
Q2 FY2025
May 5, 2025Miss
EPS Actual
-$0.50
EPS Est.
-$0.44
EPS Surpr.
-13.6%
Revenue
$0.01B
Q1 FY2025
Feb 28, 2025Miss
EPS Actual
-$0.53
EPS Est.
-$0.44
EPS Surpr.
-20.4%
Revenue
$0.00B
Q4 FY2024
Nov 6, 2024Miss
EPS Actual
-$0.34
EPS Est.
-$0.33
EPS Surpr.
-3.0%
Revenue
$0.03B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.38 | $-0.21 | $-0.06 | 3 |
| Q3 FY2028 | $-0.38 | $-0.21 | $-0.06 | 2 |
| Q2 FY2028 | $-0.38 | $-0.21 | $-0.06 | 2 |
| Q1 FY2028 | $-0.38 | $-0.21 | $-0.06 | 3 |
| Q4 FY2027 | $-0.36 | $-0.20 | $-0.05 | 2 |
| Q3 FY2027 | $-0.39 | $-0.22 | $-0.06 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.1B | 2 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 6, 2026 | +26.7% | $3.37 | $3.43 | +1.78% |
| ▲ Q1 FY2026 | Feb 25, 2026 | +25.0% | $3.53 | $3.77 | +6.80% |
| ▲ Q4 FY2025 | Nov 5, 2025 | +5.3% | $5.00 | $4.96 | -0.80% |
| ▼ Q3 FY2025 | Aug 5, 2025 | -17.1% | $5.80 | $5.53 | -4.66% |
| ▼ Q2 FY2025 | May 5, 2025 | -13.6% | $5.70 | $4.76 | -16.49% |
| ▼ Q1 FY2025 | Feb 28, 2025 | -20.4% | $7.67 | $7.51 | -2.09% |
| ▼ Q4 FY2024 | Nov 6, 2024 | -3.0% | $6.82 | $6.97 | +2.20% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -14.3% | $6.37 | $6.64 | +4.24% |
Q2 FY2026+1.78%
Report Date
May 6, 2026
EPS Beat/Miss
+26.7%
Price Before
$3.37
Price After
$3.43
Q1 FY2026+6.80%
Report Date
Feb 25, 2026
EPS Beat/Miss
+25.0%
Price Before
$3.53
Price After
$3.77
Q4 FY2025-0.80%
Report Date
Nov 5, 2025
EPS Beat/Miss
+5.3%
Price Before
$5.00
Price After
$4.96
Q3 FY2025-4.66%
Report Date
Aug 5, 2025
EPS Beat/Miss
-17.1%
Price Before
$5.80
Price After
$5.53
Q2 FY2025-16.49%
Report Date
May 5, 2025
EPS Beat/Miss
-13.6%
Price Before
$5.70
Price After
$4.76
Q1 FY2025-2.09%
Report Date
Feb 28, 2025
EPS Beat/Miss
-20.4%
Price Before
$7.67
Price After
$7.51
Q4 FY2024+2.20%
Report Date
Nov 6, 2024
EPS Beat/Miss
-3.0%
Price Before
$6.82
Price After
$6.97
Q3 FY2024+4.24%
Report Date
Aug 8, 2024
EPS Beat/Miss
-14.3%
Price Before
$6.37
Price After
$6.64
Avg Beat Reaction+2.59%
Avg Miss Reaction-3.36%
Beat Rate3 / 8 quarters
Largest Move-16.49% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RXRX ends December
Recursion Pharmaceuticals, Inc. (RXRX) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $-0.22 — beating the analyst consensus of $-0.30 by +26.7%. RXRX has beaten EPS estimates for 3 consecutive quarters. The next RXRX earnings date is expected around September 1, 2026.
Each quarter, investors track RXRX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RXRX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RXRX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RXRX earnings · 5 questionsRecursion Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. RXRX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RXRX historically reports after market close (AMC).
RXRX earnings datewhen is RXRX earningsRXRX next earnings datewhen does RXRX report earningsRXRX earnings calendar
▸ Source: FMP · Recursion Pharmaceuticals, Inc. SEC filings · US GAAP · Recursion Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026